Skip to main content

Table 1 Baseline demographics and disease characteristics (Safety population)

From: Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD

Parameter Patients (N = 61)
Age (years), mean (SD) 66.0 (6.1)
Male gender, n (%) 43 (70.5)
Race, n (%)
 Caucasian 60 (98.4)
 Asian 1 (1.6)
BMI (kg/m2), mean (SD) 26.0 (4.3)
Time since first COPD diagnosis (years), mean (range) 9.51 (1.8 to 21.0)
Smoking status at screening, n (%)
 Ex-smoker 27 (44.3)
 Current smoker 34 (55.7)
Post-bronchodilator FEV1 (L), mean (SD) 1.30 (0.42)
Post-bronchodilator FEV1 (% predicted), mean (SD) 50.2 (11.8)
 50 to 70% predicted, n (%) 33 (54.1)
 30 to 50% predicted, n (%) 28 (45.9)
COPD Assessment Test, mean (SD) 20.7 (5.8)
Baseline Dyspnea Index, mean (SD) 6.2 (1.9)
Sputum characteristics, mean (SD)
 Total cell count (× 106/g) 5.69 (20.26)
 Neutrophil cell count (× 106/g) 4.82 (8.04)
 Macrophage cell count (×106/g) 0.354 (0.319)
 Eosinophil cell count (× 106/g) 0.142 (0.230)
 Lymphocyte cell count (×106/g) 0.007 (0.011)
 Neutrophil % 82.7 (9.46)
 Macrophage % 11.0 (7.81)
 Eosinophil % 3.60 (4.27)
 Lymphocyte % 0.180 (0.267)
 Epithelial cells % 2.50 (3.80)
  1. Abbreviations: BMI body mass index, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s